je.st
news
Exclusive: Biogen prices hemophilia drug on par with older therapies
2014-04-18 21:08:28| Biotech - Topix.net
Biogen Idec Inc is pricing its newly-approved long-acting hemophilia drug to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.
Tags: par
prices
older
drug
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||